ClinicalTrials.gg
RecruitingNCT06292104Updated Jul 17, 2026

Phenotyping of Postural Orthostatic Tachycardia Syndrome (POTS)

An observational study in Postural Orthostatic Tachycardia Syndrome, sponsored by University of Texas Southwestern Medical Center. Recruiting at 1 site in United States. Open to participants aged 14 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by University of Texas Southwestern Medical Center · Observational

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
350
Ages
14 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies in Postural Orthostatic Tachycardia Syndrome with a site in United States — 19 open to participants now, 42 under way, none of them phase 3. Postural Orthostatic Tachycardia Syndrome · United States.

Planned enrollment
6th of 25
350 · median 100
Started
2024
with 7 others
Observational
25 of 92
8 open now
Primary completion
2028-12
later than 27 of 41 live
Registered
76th of 92
by date

Among the 92 studies in Postural Orthostatic Tachycardia Syndrome with a site in United States, this one is the 6th largest by planned enrollment of the 25 observational ones that give a count, is one of 8 that started in 2024, is one of 25 observational ones, reaches primary completion later than 27 of the 41 other live ones, and was the 76th registered.

Postural Orthostatic Tachycardia Syndrome

136 studies on the registry are indexed under Postural Orthostatic Tachycardia Syndrome; 42 are open to participants now.

Browse Postural Orthostatic Tachycardia Syndrome studies →

Open to participants now

19 of the 92 studies in Postural Orthostatic Tachycardia Syndrome with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Postural Orthostatic Tachycardia Syndrome studies recruiting now, 9 (31%) set no upper age limit and 16 (55%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 14 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Postural Orthostatic Tachycardia Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is an observational study to deeply phenotype the disorder of POTS using multiple testing modalities.

Read the detailed description

This comprehensive multimodality deep phenotyping will improve the diagnostic approach, inform the development of new treatments, and allow the targeting of therapies to specific POTS patients. The investigators will further identify the diagnostic tools, biomarkers, and clinical outcome measures most relevant to defining the disorder in clinical practice.

The specific aim is to (1) Define clinical POTS classifications from multimodal clinical and laboratory data, (2) address exercise tolerance in POTS using metabolomic assessments, (3) evaluate novel POTS-specific patient outcome measures and (4) evaluate one year outcome data for POTS

Specific research tests will include blood work (for immunophenotyping and neurohormonal assessments), autonomic function testing, skin biopsy (to evaluate intraepidermal nerve fiber density), CO (Carbon Monoxide) rebreathing (for quantitative measurement of plasma volume and red blood cell mass), patient surveys (to characterize symptom profile and disease impact). Blood biosamples will be stored as a repository for future research questions.

03

Conditions studied

  • Postural Orthostatic Tachycardia Syndrome
04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

POTS patients and Normal Control

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

POTS Patients

  • Age ≥ 14 years, able to provide (assent with parental consent for age \< 18) and comply with procedures
  • Meets consensus criteria for POTS: (1) sustained increase in heart rate ≥ 30 bpm above supine baseline within 10 min of quiet standing or upright tilt (≥ 40 bpm in individuals 12 to 19 years of age) OR sustained upright HR (heart rate) >120 bpm, (2) absence of orthostatic hypotension, (3) symptoms with standing that improve with sitting or lying down, (4) resting supine heart rate \< 100 bpm, (5) orthostatic symptoms present for at least 6 months
  • Stable oral medication regimen for at least 14 days

Non-POTS Control Patients

  • Healthy women, age 18 - 30 years, able to provide informed consent and comply with study procedures
  • Does NOT meet consensus criteria for postural tachycardia syndrome
  • No symptoms of orthostatic intolerance or dysautonomia. No history of other major medical disorder
  • Resting supine heart rate \< 100 bpm

Exclusion criteria

Exclusion Criteria:

None of the following exclusion criteria:

  • Use of amphetamine-type stimulants, diuretics, selective norepinephrine reuptake inhibitor, anticholinergic medications (including tricyclic antidepressant medications), fludrocortisone, desmopressin in past 14 days
  • Use of other autonomic drugs (adrenergic agents, pyridostigmine, droxidopa, triptans, ivabradine) in past 48 hours
  • Currently receiving IVIG (Intravenous immunoglobulin), subcutaneous IgG (Immunoglobulin G), or any medication (in past year)
  • Infusion of iv fluids in past 7 days
  • History or evidence of another condition explaining symptoms or orthostatic tachycardia (e.g. structural heart disease, CSF (Cerebrospinal fluid) hypovolemia, or severe traumatic brain injury)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
350 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • POTS (Postural Orthostatic Tachycardia Syndrome)

    Patients meeting clinical criteria for postural orthostatic tachycardia syndrome who meet other criteria for inclusion.

    Diagnostic Test: multimodal diagnostic testing

  • Healthy matched controls

    Age and sex matched controls

    Diagnostic Test: multimodal diagnostic testing

Interventions

  • Diagnostic testmultimodal diagnostic testing

    Serological testing, cardiac MRI, skin biopsy, cardiovascular testing, blood volume measurements

06

What researchers measure

Primary outcomes

  1. Phenotyping POTS

    Assignment of participant to a phenotypic group(s) based on analysis of multimodal data

    Time frame: 2 weeks

  2. Natural history

    Patient reported functional and subjective change. Surveys including COMPASS31 (Composite Autonomic Symptom Score-31) on a score of 0-100. Higher scores indicate more severe autonomic symptoms

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Raj SR, Bourne KM, Stiles LE, Miglis MG, Cortez MM, Miller AJ, Freeman R, Biaggioni I, Rowe PC, Sheldon RS, Shibao CA, Diedrich A, Systrom DM, Cook GA, Doherty TA, Abdallah HI, Grubb BP, Fedorowski A, Stewart JM, Arnold AC, Pace LA, Axelsson J, Boris JR, Moak JP, Goodman BP, Chemali KR, Chung TH, Goldstein DS, Darbari A, Vernino S. Postural orthostatic tachycardia syndrome (POTS): Priorities for POTS care and research from a 2019 National Institutes of Health Expert Consensus Meeting - Part 2. Auton Neurosci. 2021 Nov;235:102836. doi: 10.1016/j.autneu.2021.102836. Epub 2021 Jun 30. PubMed 34246578 ↗
  • Bryarly M, Phillips LT, Fu Q, Vernino S, Levine BD. Postural Orthostatic Tachycardia Syndrome: JACC Focus Seminar. J Am Coll Cardiol. 2019 Mar 19;73(10):1207-1228. doi: 10.1016/j.jacc.2018.11.059. PubMed 30871704 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Dec 2028, 57 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2024
First posted
Mar 4, 2024
StartActual
Mar 5, 2024
Primary completionEst.
Dec 2028
CompletionEst.
Jan 2029
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06292104
Responsible party
Steven Vernino MD PhD (PROFESSOR, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Mar 4, 2024
Start date
Mar 5, 2024
Primary completion
Dec 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Jul 17, 2026

Study contacts

Steve Hopkins
Contact
steve.hopkins@utsouthwestern.edu
214-648-9275
Steven Vernino, MD PhD
principal investigator · University of Texas Southwestern Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion